Imeglimin

An oral antidiabetic medication

Imeglimin
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number
PubChem
DrugBank
ChemSpider
KEGG

Imeglimin is an oral antidiabetic medication used in the management of type 2 diabetes mellitus. It belongs to a novel class of oral hypoglycemic agents known as the glimins. Imeglimin is unique in its mechanism of action, targeting mitochondrial bioenergetics to improve insulin sensitivity and reduce hepatic glucose production.

Mechanism of Action

Imeglimin acts by modulating mitochondrial function, which is crucial in the pathophysiology of type 2 diabetes. It enhances insulin sensitivity in muscle tissue, reduces hepatic glucose output, and improves pancreatic beta-cell function. This multifaceted approach helps in maintaining blood glucose levels within the normal range.

Pharmacokinetics

Imeglimin is administered orally and is absorbed in the gastrointestinal tract. It undergoes minimal metabolism and is primarily excreted unchanged in the urine. The pharmacokinetic profile of imeglimin supports its use as a twice-daily medication, providing sustained glucose control throughout the day.

Clinical Use

Imeglimin is indicated for the treatment of type 2 diabetes, particularly in patients who have not achieved adequate glycemic control with other oral antidiabetic agents. It can be used as monotherapy or in combination with other medications such as metformin, sulfonylureas, or DPP-4 inhibitors.

Side Effects

Common side effects of imeglimin include gastrointestinal disturbances such as nausea and diarrhea. These side effects are generally mild and tend to resolve with continued use. Imeglimin is well-tolerated, with a safety profile similar to other oral antidiabetic agents.

Development and Approval

Imeglimin was developed by Poxel, a pharmaceutical company specializing in metabolic disorders. It has undergone extensive clinical trials to evaluate its efficacy and safety in patients with type 2 diabetes. Imeglimin has been approved for use in several countries and is undergoing further evaluation for approval in additional markets.

Related pages

• Type 2 diabetes mellitus
• Insulin resistance
• Oral hypoglycemic agents
• Mitochondrial function

• 

  Imeglimin